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Abstract
A proportion of MYC translocation positive diffuse large B-cell lymphomas (DLBCL) harbour a BCL2 and/or
BCL6 translocation, known as double-hit DLBCL, and are clinically aggressive. It is unknown whether there are
other genetic abnormalities that cooperate with MYC translocation and form double-hit DLBCL, and whether
there is a difference in clinical outcome between the double-hit DLBCL and those with an isolated MYC trans-
location. We investigated TP53 gene mutations along with BCL2 and BCL6 translocations in a total of 234
cases of DLBCL, including 81 with MYC translocation. TP53 mutations were investigated by PCR and sequenc-
ing, while BCL2 and BCL6 translocation was studied by interphase fluorescence in situ hybridization. The
majority of MYC translocation positive DLBCLs (60/815 74%) had at least one additional genetic hit. In MYC
translocation positive DLBCL treated by R-CHOP (n5 67), TP53 mutation and BCL2, but not BCL6 transloca-
tion had an adverse effect on patient overall survival. In comparison with DLBCL with an isolated MYC trans-
location, cases with MYC/TP53 double-hits had the worst overall survival, followed by those with MYC/BCL2
double-hits. In MYC translocation negative DLBCL treated by R-CHOP (n5 101), TP53 mutation, BCL2 and
BCL6 translocation had no impact on patient survival. The prognosis of MYC translocation positive DLBCL crit-
ically depends on the second hit, with TP53 mutations and BCL2 translocation contributing to an adverse
prognosis. It is pivotal to investigate both TP53 mutations and BCL2 translocations in MYC translocation posi-
tive DLBCL, and to distinguish double-hit DLBCLs from those with an isolated MYC translocation.
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Introduction
Diffuse large B-cell lymphoma (DLBCL) represents
30–45% of adult cases of non-Hodgkin lymphoma
(https://www.hmrn.org/statistics) [1], accounting for
more than 80% of aggressive lymphomas. The addi-
tion of rituximab has significantly improved the treat-
ment outcome of patients with DLBCL. Nonetheless,
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a significant proportion of DLBCLs show primary
treatment failure (10%), partial response (15%) or
relapse after initial response (20–30%) to R-CHOP
(rituximab, cyclophosphamide, doxorubicin, vincris-
tine and prednisone), the current first line treatment
for this malignancy [2]. A number of biomarkers
have been investigated with the aim of predicting
treatment outcome at diagnosis and identifying those
that may benefit from novel therapeutic strategies,
but only a few have proven to be clinically useful
due to lack of reproducibility (immunohistochemis-
try-based markers) and/or difficulty of routine clini-
cal application (molecular subtypes by gene
expression profiling) on formalin-fixed paraffin-
embedded diagnostic tissue biopsies [3–5]. Among
the many biomarkers investigated, MYC chromosome
translocation is widely accepted and used in routine
clinical practice.
The MYC translocation occurs in 5–15% of
DLBCL, and is usually associated with a complex
pattern of genomic alterations [6–12]. A proportion
(21–83%) of DLBCLs with MYC translocation also
harbour a BCL2 and/or BCL6 translocation, known as
‘double-hit’ or ‘triple-hit’ lymphoma. Patients with
‘double-hit’ DLBCL commonly show aggressive
clinical features and respond poorly to currently
available treatments, with a median survival less than
1.5 years [6]. However, it remains controversial
whether DLBCL with MYC single translocation has a
different prognosis from that with MYC/BCL2 double
translocation. For example, the recent studies by Cuc-
cuini et al [13], Aukema et al [6] and Valera et al
[14] showed a similar poor overall survival between
DLBCL with MYC single translocation and those
with MYC double translocations. In contrast, the stud-
ies by Johnson et al, Green et al and Landsburg et al
demonstrated no adverse impact of MYC single trans-
location in DLBCL, while cases with MYC/BCL2
double translocations had a very poor outcome
[15–17]. Although the reasons underlying the dis-
crepancies between these studies are unclear, poten-
tial factors that may account for the discrepancies
could include the small numbers of cases investi-
gated, variations in clinicopathological parameters
(age, stage, international prognostic index [IPI]) and
a variable presence of additional genetic changes
such as TP53 mutation that modifies the prognostic
value of MYC translocation.
MYC drives cell proliferation but also sensitizes
cells to apoptotic stimuli, which provides a safe-
guard to prevent any potential MYC induced malig-
nant transformation. The MYC mediated
proapoptotic activity is largely through the activa-
tion of the p19(ARF)-MDM2-TP53 pathway and
repression of the apoptosis inhibitor BCL2 [18,19].
There is extensive literature showing that MYC
requires cooperating events to abrogate its proapop-
totic activities to exert its full oncogenic potential,
and both expression of BCL2 and loss of TP53
function cooperate with MYC translocation in lym-
phomagenesis [18–21]. In DLBCL, TP53 mutations
are found in 20% of cases and are significantly
and independently associated with poor overall sur-
vival of both activated B-cell like (ABC) and ger-
minal centre B-cell like (GCB) DLBCL treated with
R-CHOP [22,23]. TP53 mutations have been
reported in cases of DLBCL with MYC translocation
[24,25], but their frequency in MYC translocation
positive DLBCL and their combined clinical impact
are unclear. In this study, we have investigated
TP53 mutations and BCL2 translocations in a large
cohort of DLBCL, and analysed their association
and clinical impact in the presence and absence of
MYC translocation.
Materials and Methods
Patients and tissue materials
A total of 234 cases of de novo DLBCL were inves-
tigated in this study. 168 cases were retrieved from
the Haematological Malignancy Diagnostic Service
(HMDS) at St James’s University Hospital, Leeds
(n5 145) and Addenbrooke’s hospital, Cambridge
(n5 23), based on the availability of lymphoma tis-
sue specimens. 153 of these cases have been classi-
fied by cell of origin (COO) using the Illumina WG-
DASL assay used in previous studies [7,26]. The
remaining 66 cases were positive for MYC transloca-
tion by interphase fluorescence in situ hybridisation
(FISH) and identified from five participating centres
where the assessment of MYC translocation status is
a part of the routine diagnostic workup of DLBCL
[27]. The diagnosis in each case was established by
two expert haematopathologists, and those defined as
B-cell lymphoma, unclassifiable, with features inter-
mediate between DLBCL and Burkitt lymphoma, in
the 2008 WHO classification were included in this
study [28]. Burkitt lymphoma, DLBCL potentially
transformed from a low grade lymphoma, cases with
HIV or primary CNS lymphoma were excluded from
this study. All the laboratory investigations described
below were based on the initial diagnostic lymphoma
tissue specimens. Ethical guidelines were followed
for the use of archival tissues for research with the
approval of the ethics committees of the involved
institutions.
126 A Clipson et al
VC 2015 John Wiley and Sons Ltd and The Pathological Society of Great Britain and Ireland J Path: Clin Res July 2015; 1: 125–133
Microdissection and DNA preparation
Haematoxylin and eosin slides were reviewed for all
cases, and crude microdissection was performed where
indicated to enrich tumour cells, ensuring that the tis-
sue area containing >60% of tumour cells was used
for DNA preparation. DNA was extracted using the
QIAamp DNA Micro Kit (QIAGEN, Crawley, UK).
The quality of the DNA samples was assessed by poly-
merase chain reaction (PCR) of variably sized genomic
fragments [29], and those with successful amplifica-
tions of >300 bp were used for mutational screening.
PCR and Sanger sequencing
Mutations in TP53 coding exons 5–10, commonly
targeted by somatic mutation in human cancer, were
investigated by PCR and Sanger sequencing using
primers and conditions detailed in supplementary
material Table S1. In each case, sequence change
was confirmed by at least two independent PCR and
sequencing experiments. The somatic mutation was
ascertained by excluding germline changes through
SNP database search and analysis of DNA prepared
from microdissected normal cells, where possible.
Interphase FISH
Chromosome translocations involving the MYC,
BCL2 and BCL6 loci were investigated using
dual-colour break-apart probes (Vysis/Abbott Labora-
tories, UK) [30]. For each probe, the mean plus three
standard deviations of false positive signals in 100
nuclei from 8 to 10 reactive tonsils was used as the
cut-off value for the diagnosis of chromosomal trans-
location. The cut-off value for MYC, BCL2 and
BCL6 break-apart probes is very similar, all being
<6%.
Statistical analyses
Rates of genetic alterations and molecular subtypes
by COO classification were compared using
difference-of-proportions tests. Survival analyses
were performed using the Kaplan–Meier method with
log-rank tests and by using the Cox proportional haz-
ards model.
Results
We investigated a total of 234 cases of primary
DLBCL, including 168 cases selected based on their
tissue availability, and 66 additional cases based on
their positivity for MYC translocation. Among the
168 cases selected based on tissue availability, the
frequencies of MYC (15/1685 8.9%), BCL2 (30/
1685 17.8%) and BCL6 (49/1675 29.3%) transloca-
tion and TP53 mutation (26/1665 15.7%) were in
line with those reported in the literature
[6,22,23,31,32]. To understand the potential onco-
genic cooperation of these genetic changes, we ana-
lysed associations across the entire patient group.
High frequencies of TP53 mutation and BCL2
translocation in MYC translocation positive DLBCL
The frequency of TP53 mutation was significantly
higher in cases with MYC translocation than in those
without the translocation (27/815 33.3% versus 23/
1515 15.2%, p 5 0.001, Figure 1A,B). However,
there was no significant difference in the frequency
of TP53 mutation between DLBCL with an isolated
MYC translocation and those with double transloca-
tions (MYC plus BCL2 or BCL6) (14/355 40% ver-
sus 13/465 28.3%, p 5 0.38). Five cases (6% within
the MYC translocation positive series) were found to
have concurrent translocations of MYC, BCL2 and
BCL6, and none of these had a TP53 mutation (Fig-
ure 1A). In addition, no differences in the spectrum
of TP53 mutations were observed between DLBCL
with MYC translocation and those without (supple-
mentary material Figure S1).
The frequency of BCL2 translocation was also sig-
nificantly higher in DLBCL with MYC translocation
than in those without (36/815 44.4% versus 20/
1535 13.1%, p5 8.74 3 1028, Figure 1B). In con-
trast, the frequency of BCL6 translocation was lower
in DLBCL with MYC translocation than in those
without (15/795 18.9% versus 46/1525 30.0%,
p5 0.065, Figure 1B).
In cases with MYC translocation, there was no evi-
dence of correlation among TP53 mutation, BCL2
and BCL6 translocation (supplementary material
Table S2). In cases without MYC translocation, there
was a positive correlation between BCL2 transloca-
tion and TP53 mutation (p5 0.048), and a negative
correlation between BCL2 and BCL6 translocation
(p5 0.034) (supplementary material Table S2).
Among the 234 cases of DLBCL investigated, 153
had data on COO-classification by Illumina WG-
DASL array from a previous study and 140 of these
cases were MYC translocation negative [4]. We, thus,
correlated COO subtypes with genetic abnormalities
in cases without MYC translocation. As expected
[33], BCL2 translocation was significantly associated
with GCB-DLBCL (p 5 0.004), although no signifi-
cant association was seen between BCL6 transloca-
tion and COO subtype (p5 0.079, supplementary
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material Table S2). There was no correlation between
TP53 mutation and COO molecular subtype.
Distinct impact of TP53 mutations, BCL2 and
BCL6 translocations on prognosis of MYC
translocation positive DLBCL
Of the 81 MYC translocation positive DLBCLs inves-
tigated, 60 (74.1%) had at least one additional
genetic abnormality, namely TP53 mutation, BCL2 or
BCL6 translocation. Of these 60 cases, 18 had three
abnormalities, including nine cases with MYC/BCL2
double translocation and TP53 mutation, four cases
with MYC/BCL6 double translocation and TP53
mutation, and a further five cases with triple translo-
cations (Figure 1A). The remaining 42 cases with a
single additional genetic abnormality included 22
with BCL2 translocation, 14 with TP53 mutation, and
six with BCL6 translocation (Figure 1A).
To investigate whether the prognosis of these MYC
translocation positive DLBCLs was affected by the
number and nature of additional genetic abnormal-
ities, we performed a series of survival analyses.
These were carried out exclusively on cases treated
with R-CHOP or equivalent regimens with a curative
intent, and included 67 cases with MYC translocation
and 101 cases without MYC translocation.
We first focused on the MYC translocation positive
DLBCL, subdivided according to the number (1 or 2)
of additional genetic abnormalities regardless of their
nature, and examined whether the number of addi-
tional genetic abnormalities impacted on patient sur-
vival. To our surprise, cases with one, but not those
with two additional genetic abnormalities, showed a
worse survival than those with an isolated MYC
translocation. Such difference might be due to an
insufficient number of the cases with two additional
genetic abnormalities for comparison. Alternatively,
Figure 1. Correlation of TP53 mutation, MYC, BCL2 and BCL6 translocation in primary DLBCL. (A) Distribution of TP53 mutation,
BCL2 and BCL6 translocation in DLBCLs with and without MYC translocation. The majority of MYC translocation positive DLBCLs har-
bour at least one additional genetic abnormality, frequently TP53 mutation or BCL2 translocation, and occasionally BCL2 translocation
plus TP53 mutation or BCL6 translocation. Black cell: positive for the genetic abnormality indicated; Grey cell: negative for the
genetic abnormality indicated; White cell: data not available. (B) Incidence of TP53 mutation, BCL2 and BCL6 translocation in DLBCLs
with and without MYC translocation. The frequency of TP53 mutation and BCL2 translocation is significantly higher in cases with
MYC translocation. t: translocation; 1ve: positive; -ve: negative; NS: no significance.
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the findings suggest that the nature rather than the
number of the additional genetic abnormalities may
be more important in influencing the prognosis of
MYC translocation positive DLBCL.
We next examined the survival of patients with
MYC translocation positive DLBCL purely according
to the status of TP53 mutation, BCL2 and BCL6
translocation. The MYC translocation positive
DLBCL with TP53 mutation had a significantly
worse overall survival than those without TP53 muta-
tion by multivariate Cox regression analysis adjusted
for age (p5 0.036, supplementary material Figure
S2C). Similarly, MYC translocation positive DLBCL
with BCL2 translocation showed a worse survival,
albeit not statistically significant, than those lacking
the translocation (supplementary material Figure
S2A). In contrast, MYC translocation positive
DLBCL with BCL6 translocation had a significantly
better overall survival than those without BCL6 trans-
location by multivariate Cox regression analysis
adjusted for age (p5 0.035, supplementary material
Figure S2B). Despite that the reference subgroup in
each of the above analyses comprised of mixed cases
that included not only those with isolated MYC trans-
location but also cases with other second hit, the
analyses, nonetheless, suggested that TP53 mutation
and possibly BCL2, but not BCL6 translocation may
have an adverse effect on patients survival. In view
of this and the small number of cases with only MYC
and BCL6 translocation, our subsequent analyses
focused on TP53 mutation and BCL2 translocation.
We divided MYC translocation positive DLBCL
into the following subgroups according to TP53
mutation and BCL2 translocation status: MYC/BCL2
double translocation with TP53 mutation, MYC single
translocation with TP53 mutation, MYC/BCL2 double
translocation, and isolated MYC translocation. In
comparison with the subgroup with isolated MYC
translocation, all other three subgroups had a signifi-
cantly worse overall survival by logrank test (Figure
2A). Interestingly, the patients with MYC/BCL2/TP53
triple hit and the cases with MYC/TP53 double-hit
appeared to be separated from those with the MYC/
BCL2 double-hit (Figure 2A). In view of these find-
ings, we combined all cases with TP53 mutation irre-
spective of the BCL2 translocation status, and these
cases had the worst overall survival (Figure 2B, sup-
plementary material Table S3). Further univariate
and multivariate Cox regression analyses adjusted for
age confirmed the significant worse overall survival
of patients with MYC/TP53 (n5 22, p5 0.0095 and
p5 0.0059 respectively) and cases with MYC/BCL2
(n5 25, p5 0.03 and p5 0.019, respectively)
double-hit in comparison with those with isolated
MYC translocation (n5 20) Figure 2B, Table 1).
Prognostic value of TP53 mutation, BCL2 and
BCL6 translocation in MYC translocation negative
DLBCL
All MYC translocation negative DLBCLs were
retrieved from HMDS, St James’s University
Figure 2. Impact of TP53 mutation and BCL2 translocation on
overall survival of patients with MYC translocation positive
DLBCL. (A) MYC translocation positive DLBCL are divided into
four subgroups: MYC/BCL2 translocation/TP53 mutation, MYC
translocation/TP53 mutation, MYC/BCL2 translocation, and MYC
translocation only. The cases with the MYC/BCL2 /TP53 triple-
hit show the worst overall survival, followed by cases with the
MYC/TP53 and those with the MYC/BCL2 double-hit. The signifi-
cant difference in overall survival between cases with the MYC/
BCL2 /TP53 triple-hit and those with isolated MYC translocation
is also shown by Cox proportional hazards regression adjusted
for age. (B) The cases with TP53 mutation are combined
together irrespective of their BCL2 translocation status. The
cases with TP53 mutation show a worse overall survival than
those with an isolated MYC translocation, being statistically sig-
nificant by Cox regression model adjusted for age (p5 0.0059,
Table 1). The cases with BCL2 translocation also show a signifi-
cantly worse overall survival than those with isolated MYC
translocation by Cox regression model adjusted for age
(p5 0.019, Table 1).
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Hospital, Leeds and Addenbrooke’s hospital, Cam-
bridge, and 101 of these cases treated with R-CHOP
had clinical follow up data. As expected, COO-
classification clearly separated these cases into dis-
tinct prognostic groups with the ABC-DLBCL show-
ing a worse overall survival by logrank test
(p5 0.011, supplementary material Figure S3D). To
our surprise, neither isolated TP53 mutation nor sin-
gle BCL2 translocation had a significant impact on
overall survival (supplementary material Figure
S3A,C). BCL6 translocation appeared to be associ-
ated with a worse overall survival; however, this was
not statistically significant by Cox regression analysis
after age adjustment (supplementary material Figure
S3B).
Discussion
This is the first study combining chromosome trans-
locations and TP53 mutation analysis in a large
cohort of DLBCL. We have demonstrated that MYC
translocation positive DLBCL had a significantly
higher frequency of TP53 mutation and BCL2 trans-
location [7], and that DLBCL with MYC transloca-
tion and TP53 mutation had the worst overall
survival, followed by cases with MYC/BCL2 double-
hits. These findings have significant implications for
using these biomarkers in the prognostic evaluation
of patients with DLBCL.
By investigating retrospectively a large cohort of
MYC translocation positive DLBCL, we showed that
the prognostic value of MYC translocation was crit-
ically influenced by the presence of the second hit,
essentially its oncogenic cooperating events. The
patients with MYC/TP53 abnormalities irrespective of
BCL2 translocation status had a significantly worse
overall survival than those with an isolated MYC
translocation. The cases with MYC/BCL2 double
translocations but wild type TP53 showed an inter-
mediate overall survival, appearing better than those
with MYC/TP53 abnormalities, but worse than those
with an isolated MYC translocation (Figure 2B).
These findings suggest that TP53 mutation may have
a more adverse impact on prognosis than BCL2 trans-
location in MYC translocation positive DLBCL. The
importance of the second hit in prognosis of MYC
translocation positive DLBCL is further emphasized
by the observation that cases with an isolated MYC
translocation appeared to have an overall survival
similar to those without MYC translocation (supple-
mentary material Figure S4). No adverse impact of
MYC single translocation in DLBCL was also
reported in some previous studies [15–17], but not
supported by others [6,13,14]. However, these previ-
ous studies did not investigate TP53 mutation and it
is unknown whether the discrepancy was caused by a
variable presence of TP53 mutation in cases with sin-
gle MYC translocation among these studies. In view
of the retrospective nature of the current study, it
remains necessary to confirm these findings in a pro-
spective study containing a large cohort of MYC
translocation positive DLBCL.
Both TP53 mutation and BCL2 translocation are
known to cooperate with MYC translocation in lym-
phomagenesis by impeding the proapoptotic activities
of MYC. In Em-Myc transgenic animals, lymphoma
development requires the acquisition of additional
genetic alterations, which commonly comprise of dis-
ruption of the p19ARF-Mdm2-p53 pathway or overex-
pression of Bcl2 [34,35]. In addition, Em-Myc mice
with lymphoma showing a loss of p53 function have
a significantly worse survival than those with lym-
phoma overexpressing Bcl2 [36]. These findings
together with our observations in this study indicate
that there is a strong selection of genetic events that
cooperates with MYC translocation during lymphoma
development, and these cooperating events are a
major determining factor in modulating the prognos-
tic impact of MYC translocation in DLBCL.
The prognostic value of BCL6 translocation in
MYC translocation positive DLBCL is unclear. The
majority of DLBCL with MYC and BCL6 transloca-
tion also had BCL2 translocation or TP53 mutation,
and the number of cases with only MYC and BCL6
translocation is small for assessing the prognostic
impact of BCL6 translocation in MYC translocation
Table 1. Impact of TP53 mutation and BCL2 translocation on overall survival of patients with MYC translocation positive DLBCL by
Cox proportional hazards regression.
Univariate analysis* Multivariate analysis adjusted for age
HR 95% CI P value HR 95% CI P value
MYC1 BCL2 translocation(n525) 5.11 1.15-22.7 0.03 6.17 1.34-28.3 0.019
MYC translocation1 TP53 mutation
(irrespective of BCL2 translocation status)(n522)
7.26 1.62-32.5 0.0095 8.74 1.87–40.8 0.0059
*In comparison with DLBCL with isolated MYC translocation; HR: Hazard ratio; CI: confidence interval.
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positive DLBCL. There was no association between
MYC and BCL6 translocation in DLBCL. In addition,
there is no direct evidence supporting critical onco-
genic cooperation between MYC and BCL6 transloca-
tion in lymphoma development. Findings from the
present and a previous study [37] suggest that BCL6
translocation appears to be associated with a better
prognosis in MYC translocation positive DLBCL,
although this differs from that observed by Pillai
et al [38]. There are several potential reasons that
might account for the discrepancy among these stud-
ies, and these include small numbers of cases with
MYC/BCL6 translocation, difference/potential bias in
case selection, variations in clinicopathological fea-
tures (age, stage, IPI) and treatment, and potential
differences in the genetic abnormalities associated
with MYC translocation among these studies. There-
fore, it is important to investigate the prognostic
value of BCL6 translocation in MYC translocation
positive DLBCL in a prospective study.
The term ‘double-hit’ lymphoma was originally
used to describe aggressive DLBCL with MYC and
BCL2 translocation, then subsequently extended to
include those with MYC and BCL6 translocation. In
light of the findings in this study and the discussion
above, the term ‘double-hit’ lymphoma should be
extended to include those with MYC translocation
and TP53 mutation. Our data clearly highlight the
prognostic significance of TP53 mutation, even more
so than BCL2 translocation, in MYC translocation
positive DLBCL. It is therefore pivotal to confirm
these findings in a prospective study and investigate
TP53 mutation status in routine clinical practice for
cases of MYC translocation positive DLBCL, in addi-
tion to the current standard investigation for BCL2
translocation.
MYC and BCL2 translocations are commonly
investigated by interphase FISH, while TP53 muta-
tion can be readily screened for by PCR and Sanger
sequencing, or a next generation sequencing-based
approach. Alternatively, DLBCL with MYC/BCL2 or
MYC/TP53 double-hit might be screened by com-
bined immunohistochemistry for MYC, BCL2 and
TP53 [15,16,23,31,32]. The challenges for such an
immunohistochemistry-based approach are reproduci-
bility, accurate assessment of the extent and percent-
age of staining positivity, and the identification of
the best cut-off value for dichotomy between positive
and negative staining results. In addition, combined
MYC and BCL2 immunohistochemistry also identi-
fies 20% of DLBCL that show concurrent MYC
and BCL2 protein expression, but no evidence of
their involvement in translocation. This group of
DLBCL appears to show an overall survival better
than the cases with MYC/BCL2 translocation, but
worse than those without these translocations
[15,16,32], and thus, should be regarded as a separate
prognostic group. In contrast, combined MYC and
TP53 immunohistochemistry would under-detect
DLBCL with MYC translocation and TP53 mutation,
as a high proportion (17%) of TP53 mutations such
as frameshift and nonsense mutations result in a trun-
cated protein product that is unlikely to be detectable
by immunohistochemistry [23].
Our findings also highlight the importance of sepa-
rating MYC translocation positive DLBCL from nega-
tive cases in biomarker validation, particularly the
genetic events associated with MYC translocation, to
avoid the confounding effect of MYC translocation.
TP53 mutations have been shown to be significantly
associated with poor overall survival in both ABC
and GCB-DLBCL treated with R-CHOP [22,23]. In
line with this, we also found a significant association
of TP53 mutation with poor overall survival in
DLBCL when MYC translocation positive cases were
included (based on unselected cases from HMDS,
Leeds /Addenbrooke’s Hospital). However, this sig-
nificant association disappeared after excluding the
MYC translocation positive cases, indicating a con-
founding effect of the translocation. Nonetheless, the
number of MYC translocation negative cases investi-
gated in this study is relatively small and the prog-
nostic value of TP53 mutation in MYC translocation
negative DLBCL remains to be elucidated.
In summary, we have shown that MYC translocation
positive DLBCL has a significantly higher frequency
of TP53 mutation and BCL2 translocation, and that
the cases with MYC translocation and TP53 mutation
had the worst overall survival, followed by cases with
MYC/BCL2 double-hits. It is critical to investigate
both TP53 mutation and BCL2 rearrangement in MYC
translocation positive DLBCL, and to distinguish
double-hit DLBCLs from those with an isolated MYC
translocation in routine clinical practice.
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SUPPLEMENTARY MATERIAL ON THE INTERNET
Additional Supporting Information may be found in the online version of this article.
Figure S1. Nature and distribution of TP53 mutations in primary DLBCL with and without MYC translocation. All mutations are reported in
the COSMIC somatic mutation database, with the exception of c.67211G>T, c.783-1G>A and R333C. There is no apparent difference in the
nature and distribution of TP53 mutation found in primary DLBCL with and without MYC translocation. trans1ve: translocation positive;
trans-ve: translocation negative; Mutations seen in the same case are indicated by the same colour scheme with the exception of those in
black.
Figure S2. Impact of TP53 mutation, BCL2 and BCL6 translocation on overall survival of patients with MYC translocation positive DLBCL.
trans1ve: translocation positive; trans-ve: translocation negative.
Figure S3. Impact of TP53 mutation, BCL2 and BCL6 translocation, and COO molecular subtype on the overall survival of patients with MYC
translocation negative DLBCL. These cases are from the Haematological Malignancy Diagnostic Service (HMDS) at St James’s University
Hospital, Leeds and Addenbrooke’s hospital, Cambridge, retrieved based on the availability of lymphoma tissue specimens. All cases included
in the survival analysis were treated with R-CHOP or a rituximab-containing equivalent regimen. trans1ve: translocation positive; trans-ve:
translocation negative; COO: cell of origin
Figure S4. Comparison of overall survival between DLBCL with isolated MYC translocation (absence of TP53 mutation, BCL2 and BCL6
translocation) and those without MYC translocation. These cases are selected based on the availability of lymphoma tissue specimens from the
Haematological Malignancy Diagnostic Service (HMDS) at St James’s University Hospital, Leeds, and Addenbrooke’s hospital, Cambridge,
and all cases included in this figure were treated with R-CHOP or equivalent regimens. Dotted lines indicate 95% confidence intervals.
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